(MENAFN- EIN Presswire)
Emphysema Treatment Industry Research
PORTLAND, OREGON, UNITED STATES, March 13, 2024 /EINPresswire / -- The emphysema treatment market is segmented by region into North America, Europe, Asia-Pacific, and LAMEA. In 2021, North America dominated the market share and is projected to maintain its leadership throughout the forecast period. This can be attributed to the high prevalence of emphysema and substantial investments in healthcare infrastructure. Furthermore, advancements in COPD medications and increased awareness about chronic obstructive pulmonary disease (COPD) are propelling market growth in this region.
Download Sample Report:
However, Asia-Pacific is poised to witness the highest growth during the forecast period. This growth is fueled by increased investments in the manufacturing of high-quality emphysema drugs. Additionally, the presence of key market players such as AstraZeneca, Novartis AG, Boehringer Ingelheim, and GlaxoSmithKline Plc., coupled with advancements in manufacturing technology, further boosts market expansion.
In Asia-Pacific, countries like India and China exhibit significant potential for market growth. India has a high prevalence of COPD due to the increasing number of smokers, particularly among males in urban areas. Similarly, China faces a high burden of COPD due to smoking, air pollution, and unhealthy lifestyles. The presence of a large patient pool and rising investments in healthcare infrastructure make Asia-Pacific a lucrative market for emphysema treatment.
Competitive Analysis
Key players in the emphysema treatment market include AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Mylan Pharmaceuticals (Viatris), Teva Pharmaceuticals, Hikma Pharmaceuticals Plc, Orion Corporation, Pfizer, Inc., and Verona Pharma. These companies employ strategies such as product launches, approvals, and contract agreements to enhance their market presence and cater to the growing demand for effective emphysema treatments.
For instance, in December 2019, Highmark and Boehringer Ingelheim announced a value-based contract for Stiolto Respimat for COPD treatment. Additionally, AstraZeneca's Breztri Aerosphere was approved in the US for COPD maintenance treatment in July 2020. Furthermore, Teva Pharmaceutical Industries Ltd. launched the first generic version of PERFOROMIST for COPD treatment in June 2021.
Key Benefits for Stakeholders
This report offers a comprehensive analysis of market segments, current trends, and estimations from 2021 to 2031, identifying prevailing market opportunities in emphysema treatment.
Porter's five forces analysis helps stakeholders understand the market dynamics and make informed business decisions.
In-depth segmentation analysis assists in identifying market opportunities and understanding regional contributions to the global market revenue.
Market player positioning facilitates benchmarking and provides insights into the competitive landscape.
The report includes analyses of regional and global trends, key players, market segments, application areas, and growth strategies in the emphysema treatment market.
Purchase Inquiry:
David Correa
Allied Market Research
email us here
+1 5038946022
Visit us on social media:
Facebook
Twitter
LinkedIn
MENAFN13032024003118003196ID1107970081
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.